Two large meta-analyses concluded that there was a significant association between B-raf mutations and adenocarcinomas in NSCLC compared with non-ADKs and no significant difference was observed in smoking and stage in patients with B-raf mutations [48,49]. The gene discussed is BRAF; the disease is adenocarcinoma.